PO Box 58871
London SE15 9BE, UK
info@cedillapublishing.com
+44 (0)7794 485294


Cedilla Publishing highly commended at 2016 BMA Medical Book Awards
We are delighted to announce that our GP pain handbook, The 10-minute consultation: persistent pain, was highly commended in the primary health care category at the 2016 BMA Medical Book Awards.

The GP judging panel commented:
"Pain management is an increasingly challenging field in general practice and this [guide] brings together a lot of useful information. It is comprehensive while concise and includes a good range from the best scientific evidence through to holistic approaches. I checked some of the sections and found them to be both accurate and up-to-date. It is a good introduction to the subject."

If you are interested in purchasing copies or translation rights, please contact Sarah Findlay on +44 (0)7794 485294 or email info@cedillapublishing.com.

News Archive

Dance lessons for the lonely - on the NHS
Mon, 15 Oct 2018 08:09:17 GMT
GPs in England are to prescribe "social" activities, such as dance and cookery lessons, to tackle loneliness.
Crackdown on painkillers amid addiction fears
Mon, 15 Oct 2018 16:11:21 GMT
Pregabalin and gabapentin to be reclassified as class C drugs from April, the government announces.
Children 'should be weighed up to age 18', report says
Mon, 15 Oct 2018 08:23:45 GMT
A report by child health experts warns England is falling behind other countries unless policies change.
England falling behind peers on child health
Mon, 15 Oct 2018 11:33:04 +0100
The Royal College of Paediatrics and Child Health (RCPCH) is calling for a properly funded, long-term plan to transform the life chances of young people, after finding that England is in danger of falling further behind its peers on child health.
Santhera?s cystic fibrosis drug POL6014 in line for orphan status
Mon, 15 Oct 2018 10:13:46 +0100
Santhera says its experimental cystic fibrosis drug POL6014 is likely to be designated an orphan drug in the next 30 days, putting the firm in line to receive regulatory and financial incentives for its further development.
Opdivo fails to hit key target in small cell lung cancer study
Mon, 15 Oct 2018 09:53:59 +0100
Bristol-Myers Squibb’s immunotherapy Opdivo did not hit the primary target of a late-stage study testing its efficacy in certain patients with small cell lung cancer.